Stock News & Analysis

Is the insurance giant stock still a buy today?

AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.

Both funds charge just 0.03% annually, but VTV's 1.9% dividend yield and lower volatility appeal to income investors, while SPTM's 1,500 holdings offer maximum diversification.

IonQ just bought a cybersecurity company.

Investors are still selling Sandisk stock today -- and they're all wrong.

The gap between Meta's AI spending and Muse's subscriptions is far too great.

iShares charges 0.32% versus State Street's 0.5%, but State Street yields 3.5% versus 2.7%. Which trade-off wins for your portfolio?

Synopsys could emerge as a major winner from the next phase of AI growth, but its ambitious 2030 targets come with important valuation risks.

It's not just retirees who are impacted by Social Security changes.

The famous "Big Short" investor is betting against one of the AI industry's hottest players.

Regional banks offer nearly double dividend yield but face steeper drawdowns. Broader financials fund delivered stronger 5-year growth with lower volatility.

One designs the chips, the other builds the machines, but their financial health and risk profiles tell very different stories.

Turn a five-figure investment into four-figure dividend income with this blue chip dividend growth stock.

This under-the-radar industrial technology stock boasts a Superscore of 71 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

Intel's foundry turnaround has resulted in heavy losses and negative free cash flow, while Qualcomm generates robust cash with half the valuation multiple.

The problem has become too big and undeniable to not bet on the solution.

AMD's 34% revenue surge outpaces Arm's 23% growth, yet Arm trades at a premium valuation, a rare disconnect that reshapes the investment case.

The stock was higher a year later after five of its seven past waits this long. What went wrong in the other two?

Schwab's ultra-low 0.03% expense ratio and $21.8 billion in assets dwarf JPMorgan's newer offering, though both funds delivered similar five-year returns despite different portfolio strategies.

Here's exactly what investors need to know about Ford and GM's path ahead with software-like margins and a rapidly growing overseas threat.